ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Akeso and RemeGen side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AkesoRemeGen
studies on the registry16683
open to participants now6742
phase 3 studies under way2518
reach primary completion within a year295
programswith a study of their own in two years1710

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAkesoRemeGen
Phase 1

Akeso: 6 of its 17 programs at phase 1

  1. AK 135phase 1
  2. AK150phase 1
  3. AK152phase 1
  4. AK154phase 1
  5. AK157D1 for injectionphase 1

and 1 more — sign in to see them all

35%
00%
Phase 2

Akeso: 5 of its 17 programs at phase 2

  1. AK139phase 2
  2. AK138D1phase 2
  3. AK146D1phase 2
  4. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2
  5. tinengotinibphase 2
29%

RemeGen: 5 of its 10 programs at phase 2

  1. Anti-c-Met/MMAE ADC RC108phase 2
  2. ABBV-1480phase 2
  3. RC278phase 2
  4. RC288phase 2
  5. telisotuzumab adizutecanphase 2
50%
Phase 3

Akeso: 6 of its 17 programs at phase 3

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. ligufalimabphase 3
  4. AK120phase 3
  5. ebronucimabphase 3

and 1 more — sign in to see them all

35%

RemeGen: 5 of its 10 programs at phase 3

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. telitaciceptphase 3
  4. RC28-E proteinphase 3
  5. tislelizumabphase 3
50%
Approved, new studies00%00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Akeso8 readouts · 1 phase 3

Akeso, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cadonilimabphase 3 · Nov 0 · NCT06341335

Akeso, Dec ’26: 4 programs whose next study reaches primary completion

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2 · Dec 0 · NCT06943820
  2. ivonescimabphase 3 · Dec 0 · NCT05689853
  3. AK139phase 2 · Dec 27 · NCT07436221
  4. ligufalimabphase 3 · Dec 30 · NCT05227664
····

Akeso, May ’27: 1 program whose next study reaches primary completion

  1. tinengotinibphase 2 · May 10 · NCT07052253

Akeso, Jun ’27: 1 program whose next study reaches primary completion

  1. AK152phase 1 · Jun 0 · NCT07301502
··

Akeso, Sep ’27: 1 program whose next study reaches primary completion

  1. AK146D1phase 2 · Sep 1 · NCT07591090
·
RemeGen3 readouts · 3 phase 3·

RemeGen, Dec ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. disitamab vedotinphase 3 · Dec 0 · NCT06221748
  2. telitaciceptphase 3 · Dec 31 · NCT07249632
····

RemeGen, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. RC148phase 3 · May 12 · NCT07462143
·····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Akeso

New programs 2

Reached a new phase 0

None

Study stopped 1

Primary completion later 1

RemeGen

New programs 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 9 in all. A program counts in each condition its studies name most.

ConditionAkesoRemeGen
Carcinoma, Non-Small-Cell Lungboth · compare here

Akeso in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. ivonescimabphase 3
  2. cadonilimabphase 3
  3. AK138D1phase 2

Their studies: Akeso’s studies of Carcinoma, Non-Small-Cell Lung in search

RemeGen in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3
  3. tislelizumabphase 3
  4. Anti-c-Met/MMAE ADC RC108phase 2
  5. ABBV-1480phase 2

and 1 more — sign in to see them all

Their studies: RemeGen’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Akeso in Breast Neoplasms: 3 programs

  1. AK138D1phase 2
  2. AK146D1phase 2
  3. tinengotinibphase 2

Their studies: Akeso’s studies of Breast Neoplasms in search

RemeGen in Breast Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. RC148phase 3

Their studies: RemeGen’s studies of Breast Neoplasms in search

Carcinoma, Hepatocellularboth · compare here

Akeso in Carcinoma, Hepatocellular: 2 programs

  1. cadonilimabphase 3
  2. tinengotinibphase 2

Their studies: Akeso’s studies of Carcinoma, Hepatocellular in search

RemeGen in Carcinoma, Hepatocellular: 2 programs

  1. tislelizumabphase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Carcinoma, Hepatocellular in search

Colorectal Neoplasmsboth · compare here

Akeso in Colorectal Neoplasms: 1 program

  1. ivonescimabphase 3

Their studies: Akeso’s studies of Colorectal Neoplasms in search

RemeGen in Colorectal Neoplasms: 2 programs

  1. RC148phase 3
  2. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Colorectal Neoplasms in search

Stomach Neoplasmsboth · compare here

Akeso in Stomach Neoplasms: 1 program

  1. cadonilimabphase 3

Their studies: Akeso’s studies of Stomach Neoplasms in search

RemeGen in Stomach Neoplasms: 2 programs

  1. disitamab vedotinphase 3
  2. tislelizumabphase 3

Their studies: RemeGen’s studies of Stomach Neoplasms in search

Carcinoma, Transitional Cellboth · compare here

Akeso in Carcinoma, Transitional Cell: 1 program

  1. AK146D1phase 2

Their studies: Akeso’s studies of Carcinoma, Transitional Cell in search

RemeGen in Carcinoma, Transitional Cell: 1 program

  1. disitamab vedotinphase 3

Their studies: RemeGen’s studies of Carcinoma, Transitional Cell in search

Hodgkin Diseaseboth · compare here

Akeso in Hodgkin Disease: 1 program

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2

Their studies: Akeso’s studies of Hodgkin Disease in search

RemeGen in Hodgkin Disease: 1 program

  1. tislelizumabphase 3

Their studies: RemeGen’s studies of Hodgkin Disease in search

Neoplasmsboth · compare here

Akeso in Neoplasms: 1 program

  1. ligufalimabphase 3

Their studies: Akeso’s studies of Neoplasms in search

RemeGen in Neoplasms: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Neoplasms in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

Akeso in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Anti-PD-1/LAG-3 Bispecific Antibody AK129phase 2

Their studies: Akeso’s studies of Squamous Cell Carcinoma of Head and Neck in search

RemeGen in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. telisotuzumab adizutecanphase 2

Their studies: RemeGen’s studies of Squamous Cell Carcinoma of Head and Neck in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Akeso 4 of 17 · RemeGen 5 of 10 programs (6 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.